Renal gluconeogenesis in clofibrate-treated rats

Area of Science:

• Biochemistry
• Pharmacology
• Physiology

Background:

• Clofibrate is a lipid-lowering drug with known effects on metabolism.
• Understanding its impact on specific organs like the kidney is crucial for comprehensive pharmacological assessment.

Purpose of the Study:

• To investigate the effects of clofibrate on renal gluconeogenesis in normal rats.
• To determine if changes in acid-base balance contribute to clofibrate's metabolic effects in the kidney.

Main Methods:

• Rats were fed a diet containing 0.3% clofibrate for varying durations.
• Biochemical measurements of serum lipids, kidney hypertrophy, and key gluconeogenic enzyme activities were performed.
• In vitro synthesis of glucose by kidney cortex slices was assessed.

Main Results:

• Clofibrate reduced serum cholesterol and triglyceride levels, accompanied by kidney hypertrophy, with effects peaking at 3 days and lasting 21 days.
• Increased activities of glucose-6-phosphatase, pyruvate carboxylase, and phosphoenolpyruvate carboxykinase were observed in the kidney cortex.
• Enhanced glucose synthesis from various precursors (glutamate, lactate, pyruvate, glycerol, malate) by kidney cortex slices was noted.
• No significant changes in blood pH or bicarbonate levels were detected.

Conclusions:

• Clofibrate administration enhances renal gluconeogenesis in rats.
• The observed enhancement of kidney glucose synthesis by clofibrate is independent of alterations in acid-base balance.